BioStem Technologies, Inc.
BSEM
$4.38
-$0.46-9.60%
OTC PK
| 06/30/2025 | 03/31/2025 | 09/30/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -33.82% | 73.08% | 2,258.90% | 2,258.90% | 6,872.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -33.82% | 73.08% | 2,258.90% | 2,258.90% | 6,872.30% |
| Cost of Revenue | -81.72% | -61.64% | 1,203.81% | 1,203.81% | 1,718.49% |
| Gross Profit | -31.29% | 80.63% | 2,366.94% | 2,366.94% | 8,104.12% |
| SG&A Expenses | -24.77% | 85.07% | 1,751.83% | 1,751.83% | 1,686.70% |
| Depreciation & Amortization | 12.20% | 4.05% | 1.43% | 1.43% | -9.83% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.11% | 80.39% | 1,679.56% | 1,679.56% | 1,636.55% |
| Operating Income | -98.72% | 13.91% | 1,605.56% | 1,605.56% | 425.02% |
| Income Before Tax | -97.93% | 18.86% | 695.05% | 695.05% | 401.23% |
| Income Tax Expenses | -67.92% | -32.69% | -- | -- | -- |
| Earnings from Continuing Operations | -108.98% | 37.61% | 543.40% | 543.40% | 320.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -108.98% | 37.61% | 543.40% | 543.40% | 320.18% |
| EBIT | -98.72% | 13.91% | 1,605.56% | 1,605.56% | 425.02% |
| EBITDA | -98.05% | 13.80% | 1,746.36% | 1,746.36% | 434.58% |
| EPS Basic | -108.76% | 34.65% | 466.49% | 466.49% | 279.15% |
| Normalized Basic EPS | -97.97% | 16.27% | 1,024.54% | 1,024.54% | 345.02% |
| EPS Diluted | -111.27% | 0.00% | 380.70% | 380.70% | 236.36% |
| Normalized Diluted EPS | -97.39% | -12.53% | 814.25% | 814.25% | 290.86% |
| Average Basic Shares Outstanding | 2.53% | 2.19% | 20.94% | 20.94% | 22.91% |
| Average Diluted Shares Outstanding | -20.13% | 35.87% | 56.54% | 56.54% | 57.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |